www.11psb.com_www.11psb.com-【庄家通吃】:白岩松:朋友圈有价值东西没那么多我跟手机不亲

www.11psb.com_www.11psb.com-【庄家通吃】

2019-10-18 19:11:27

字体:标准

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.

  Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.

  HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."

  Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.

  Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."

  HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.

  HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.

  Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."Today,Amandaleadsaprogramevaluatingthetreatmentofacutebacterialinfections.Asprogramlead,Amandahasoversightfortheentirelate-stagedevelopmentprogram."Weareworkingtowardbeinginapositiontosubmitourfirstregulatoryfiling,somostofouractivitiesarefocusedonthatrightnow.It'sanexcitingtime."Italsoisatimeofrapidchangeintheregulatorylandscapeforantibiotics."Multi-drug-resistantbacteriaareapublichealthcrisis,"saysAmanda."Becauseofthiscrisis,theU.S.FoodandDrugAdministration(FDA)andotheragencieshaveissuedguidanceforstreamlineddrugdevelopment,andhavecreatedopportunitiesforenhancedcommunicationbetweenregulatorsandcompaniesdevelopingdrugstotreattheseinfections.Myprogramisinthemiddleofthisevolution,whichisbothexcitingandchallenging."InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”

  Asaresearcher,Iusedmicroscopestobetterunderstandhowcellswork.Overtheyears,I’veelevatedandwidenedmyfocus,workingwithpolicymakerswhowanttoapplyscienceandtechnologytosolvemajorhealthchallenges.Antibioticresistanceisoneofthem.Today,somepatientshavebacterialinfectionsthatdoctorshavegreatdifficultytreatingbecauseofresistanceandpublichealthexpertswarnthattheproblemwillonlygrowifwedon’tworktoaddressitnow.Tostart,weneedtoensurethatantibioticsareusedappropriatelysothattheydonotbecomeobsoleteduetoresistance.Ideally,scientistswilldevelopentirelynewwaystotreatandpreventinfections.Bothapproacheswillrequirenewpoliciestoencourage,rewardandsustaininnovationovertime.Butlikemostcomplexproblems,there’snosimplefixandsciencewillonlybepartofthesolution.Collectively,antimicrobialresistanceisforcingpolicymakerstorethinkthewaydiseasesaremanaged,fromhowwediagnoseandtrackinfectionstohowwedevelopanduseanti-infectives.Thegoodnewsisthatpolicymakersaroundtheworldrecognizethepotentialthreatofuncheckedantimicrobialresistanceandkeystakeholders—includinggovernments,healthcareproviders,publichealthgroupsandindustry—havepledgedaction.I’mproudtoworkforacompanythatispartofthediscussion,andthesolution.HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

  InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”InJanuary1994,withmuchoftheEastCoastburiedinsnow,MSDscientistsinPennsylvaniaconfrontedtheelementstocontinuetheirworkinthelab.TheWashingtonPostlaterdescribedthemas“braveorstupid,”buttheresearchersweremotivatedbysomethingbig:thepotentialforabreakthroughdiscoveryinthefightagainstHIV.Sixyearsearlier,MSDhadbeenthefirsttoprovethatinhibitingtheHIVproteaseenzymecouldpreventthevirusfromreplicating.Thatdiscovery,however,wasonlythebeginning.Shortlythereafter,theresearchersandscientistsenduredanumberofdiscouragingsetbacks,includingthefailureofapromisingcompoundandthedeathofoneofourleadresearchersintheLockerbiebombingofPanAmflight103.Butourcolleagueswouldnotbedeterredintheirsearch.Michael(Mike)Thien,Ph.D.,whocurrentlyheadsupGlobalScience,TechnologyandCommercializationforMSDManufacturingDivision,wasoneofthosescientists.“Wehadagreatsenseofurgencytotheworkthatweweredoing”“Itwasabigchallenge.Theproductitselfwasprobablythemostcomplexchemicalentitythatwehadevermade,”Mikeremembers.“ButwefelteverydaytherealpressureofthefactthattherewerenogoodtherapiesforHIVatthetime.Andsothataddedagreatsenseofurgencytotheworkthatweweredoing.Noonesaidthattheycouldn'tdothisorthat.Noonesaidtheycouldn'tstayafterandworklonger.”Rememberinga‘watershed’momentinhislifeAlltold,MSDinvestedmorethan0million(.3billionintoday’sdollars)intheproject,whichincludedamassiveclinicaltrialinvolvingsome4,800patientsin11countries.Ourcommitmentwasfinallyrewardedin1996,whentheFoodandDrugAdministration(FDA)approvedourtreatmentforHIVinjust42days,thefastestapprovalinFDAhistory.Butbeforethisbreakthrough,Mikeonlyencounteredwhathedescribedas“failures”inhiswork.“Overthecourseofatwoandahalfyearperiod,Iwentfromworkingoneightthingsthatfailedtoonethingthatworked.ButthatonethingthatworkedWell,thatwasawatershedmomentinmylife.”It’ssomethingheencouragesotherscientistsandresearcherstoremember.“Therearen’talotofbusinesseswherewhensomethingentersclinicaltrials,itonlyhasaninepercentchanceofmakingitallthewaythroughtothemarketplace,”hesays.“Whenyou’redoingdevelopmentworkinourbusiness,youaregoinginwiththephilosophythat,yes,you’regoingtogettoworkonalotofgreatthings.Butyou’llbereally,reallyluckyifoneofthemisgoingtothemarketplacetomakeadifference.”Whatisinstoreforthefutureforthisdistinguishedscientist–andMSDAsheentershis27thyearatthecompany,MikecurrentlyrunsthescientificandtechnologyareainmanufacturingatMSD.“Igettodothreethings:Fromamanufacturingperspective,myareaworksonthelastbitsofdevelopmentforprocessesandproductsandpackagingfornewproducts–wegetthemreadytobemanufactured.Thesecondthingisgettingtheseverycomplextechnicalprocessesreadyforthemanufacturingfloor.Theyhavechallengesfromtimetotime.SoIoverseethetechnicalteamstoidentifywhywemightbehavinganissueandhowtofixit.ThelastthingI’mresponsibleforareallofourcapitalassets--allofthebuildingsandfactorieswebuild.”He’sstillasbusyasever,butMikeonlyseesthebrightsideofallofthework.“TherearesomethingsyoucandoworkingforacompanylikeMSDthatyouwouldneverbeabletodoinacademia,whereIwouldneverbeabletodevelopanewoperatingmodelorcomeupwithanewmanufacturingprocess.Iwouldneverbeabletosaythatmyworkcontributedtohelpthelivesofhundredsofthousandsofpeople.Thosearethethingsyoudon’tgettosayasanacademician,”henotes.“ButatacompanylikeMSD,yougettosaythemwithpride.”Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.

  UseSunscreenNosunscreenprotectsyoucompletely–butitdoeshelp.TheSkinCancerFoundationrecommendsusingabroadspectrum(UVA/UVB)sunscreenwithanSPFof15orhighereveryday.Ifyou’llbeoutdoorsforalongerperiodoftime,tryusingawater-resistant,broadspectrum(UVA/UVB)sunscreenwithanSPFof30orhigher.TheAmericanCancerAssociationsuggestsapplyingaboutanounce(think:ashotglassorpalmful)tocoverthearms,legs,neck,andfaceoftheaverageadultandadministeringitabout30minutesbeforesunexposuretohelpitbindtoyourskin.Besuretoreapplyeverytwohoursorsotohelpkeepyouprotectedandpayspecialattentiontothoseareasofskinwhichmaynotbefullyprotectedbyclothing.Remember:SunscreenbeforeyoursuitIfyouwantextraprotectionfromthesun,theSkinCancerFoundationsuggestsapplyingyoursunscreenbeforeyouputonyourbathingsuit.WhyTworeasons:Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:Aseveryoncologistknows,itscancersunpredictabilitythatmakesthediseasesuchachallenge.Whenwediscoverwaystoblockonerouteoftumorgrowth,cancercellsfigureoutanotherwaytogrow,spread,andpotentiallykill.Andamongcancertypes,lungcancerisaparticularlyelusivetarget.Thereasonisbiological.Researchersblamelungcancershighmutationalload.Inotherwords,lungcancerchangessoquicklythatfindingconsistentwaystodestroyitisoftenalostcause.Andsotheoutcomeissobering:Lungcancerkillsmorepeoplethancolon,breastandprostatecancers–combined.Thisisarealityforthoseofuswhotreatlungcancerpatientsonadailybasis.Althoughthesestatisticsaredisheartening,Idobelieveweliveinahopefultime.WhenIseepatientswhoknowtheyarefacingadifficultjourney,theyoftenwanttoknowwhattheiroptionsare.Asaphysicianandresearcher,itismygoaltohelppatientsidentifythebestpathforward,andideally,contributetothedevelopmentofnewoptionsthatmayhelpintheirtreatment.Asrecentlyasafewyearsago,patientswouldhavebeenseverelylimitedintheirchoices.Now,therearemultiplepathsforward.Ourunderstandingofthebiologyoflungcancerhastakenleapsthatallowustohelppredict,withmuchgreaterprecision,whichdrugswillhavethegreatestlikelihoodofsuccessforwhichpatients.Somelungtumorsarevulnerable,foratime,becausetheyweresetinmotionbyasinglemutation–referredtoasadrivermutation–thatcanbemorepreciselytargeted.Sowhilethereisstillmuchtobedone,wearealsomakingstrides.Itsprogresslikethisthatallowsustocontinuetohavehope.CompaniessuchasMSDunderstandhowenormoustheunmetneedhasbeeninlungcancer.Ourownliveshavebeentouched,andsometimesdevastated,bythedisease.Ourpassiontowardsfindingnewwaystomanagethediseasecontinues,onestep,onepatient,onebreakthrough,atatime.

  Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:HowDiverseTeamsMaketheStrongestOnesBeckyalsoworkstobuilduponMSD’scultureofscientificexcellenceandcommitmenttodiversityandinclusionthroughherworkasamentor,co-leadofourwomeninchemistrysymposium,andactivememberofthe.“I'mabigchampionofwomeninchemistryanddiversityingeneral.Ithinkdiverseteamsarecertainlyourstrongestteams,andIthinkwe,aswomen,havealottoadd,”shesays.“IwanttomakesurethatallthebestwomenarecomingtoMSD,sohavingagreatcultureandagreatcommunityisreallyimportant.”Becky,whoalsohelpsrunrecruitmentinherdepartment,pushesherorganizationtomakeemergingfemalescientistsandchemistsawareoftheopportunitieshere.Mostrecently,they’vepartneredwiththeACS,andhavecreatedthetorecognizeemergingfemalechemists.AwardeesareassignedMSDmentorsandtheopportunitytopresenttheirresearchatanawardssymposiumheldduringtheannualACSnationalmeeting.Sheisalsothe2018winnerofthe.Althoughshenotesshemaybebiasedabouthergroup(shedoeshaveahandinrecruiting,afterall),BeckyisconfidentthatMSDattractsthetoptalentinthefield.“We'vebeenhiringalotoverthepastcoupleofyears,andit'sreallyinvigoratedourgroup.Wehaveyouthfulenergycoupledwithourmoreexperiencedfolks,whoprovidedeepinsightinhowtosuccessfullycarryoutprocesschemistry.It’sawonderfulcommunity.”Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:

  Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould–anddid–pushuselessorharmless“cures”onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine’seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial–comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment–haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround“breakthrough”productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe’vebeenabletousethesenewtools.Wehavehadtheopportunity–whentheearlytrialsshowpromise–toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Ouremployeesacrosstheglobehavejoinedusinthefighttoendmaternalmortalitybycommittingtheirtimeandresources-fromorganizingpost-natalkitseventstoprovidemuch-neededitemstonewmothersin,tohostingusedcellphonedrivestoprovidemobilehealthtechnologyinNepal.Duringthisyear’sMayisforMothers,we’rediscussingtheroleandimpactmomshaveontheirchildren,family,communityandnation.WeliketocallthistheMomEffect.ThroughoutMSDofficesaroundtheworld,ouremployeesareparticipatinginactivitiestoraiseawarenessandsupportmaternalhealthefforts.Learnhowyoucangetinvolvedandjoinushere:Despitenewdiscoveriesandimprovementsinthecareofpeoplewithbladdercancer,there'sstillasignificantneedforscientificadvancementinthisarea.AtMSD,wehavemadeitourmissiontohelpaddressthisneedthroughinnovativeresearch.Bladdercancersaredividedintovarioustypesdependingonthetypeofcellsthatbecomecancerous.Themostcommontypeisurothelial(transitionalcell)carcinoma,whichmostoftenstartsintheurothelialcellsliningtheinsideofthebladder.Ifnotcaughtearlyenough,bladdercancercanbecomeinvasiveandspreadtootherorgans,sometimesleadingtoaradicalcystectomy(bladderremoval).Ourbladdercancerteamhasdedicateditselftoresearchingtheunmetneedsofpatients.Workingacrossfunctions-andcontinents-theteamhasworkedtirelesslyandcollaborativelytouncoversolutionsandhelppatientswithbladdercancer.

责任编辑:www.11psb.com_www.11psb.com-【庄家通吃】社友网:未经授权不得转载
关键词 >>

继续阅读

热新闻

热话题

热门推荐

关于我们 联系我们 版权声明 网站地图
百站百胜: 中方:将继续鼓励印巴相向而行通过对话化解分歧 江苏化工厂发生爆炸当地民众为记者免费提供口罩 德勤:美国消费者平均订阅3个视频流媒体服务 毅德国际王连洲退任独立非执行董事等职务岳峥接任 众泰T300小强版上市售价4.59-5.59万元 准状元已经心有所属?他表态很乐意为这队打球 美团B类股票今日解禁投行:持续看好中长期发展前景 全新小型SUV/搭1.6L动力科赛5申报图发布 乐信、陆金所入选哈佛案例Fintech成中企出海新名… 今天的记者会上,小新向总理问了一个“天大”的问题… 最被看好十大港股:瑞银升新华保险至50.2元维持买入 熊黛林与甄子丹切磋武艺,网友:辣妈好霸气! 足协超低规格对待的卡纳瓦罗双线执教能撑住吗 德国商报:德银和德国商业银行的员工共同反对合并 黄奕谈女儿被谣言中伤:感情风波的后果自己承担 为什么爱哭?包文婧:就是个情绪波动比较大的人 侯佩岑穿短裤秀纤细长腿头发微卷笑容甜美气质佳 大众又推5款纯电动!看看你都认识吗 干死联盟所有超巨不低头!火箭球迷爱死的旧将 田径亚少赛中国12金三连霸短跑跳高新人成绩瞩目 完美之外还要精益求精葱桶议论技术为啥被压级 新西兰恐袭枪手直播还发自白书将成恐袭新常态? 美国参议院投票否决川普宣布的国家紧急状态 巴塞尔表展还没开门新款我们这就先看起来了 SHINee崔珉豪申请海军陆战队服役预计将4月入伍 30+6+5三分感受佛之怒扣历史第一第二都在这 木村光希在台湾过白色情人节想品尝不同甜点(图) 26分创新高!末节导演16-0狂潮!吴前真是大腿 潘功胜、戴相龙、姜建清激辩地方商业银行股份制改革 中国联通2月4G用户达2.26亿户净增283.9万户 大帝生日惊现最强撞脸怪!库里不打球去伴唱了? 本年度最后一个超级月亮将现收好“观天时刻表” 澳优绩后见获利盘现跌逾4% 黑涩会美眉13年后五人合体庆生网友:都变成女神 舜宇光学去年纯利24.9亿人民币跌14%股息56.8… 小米奖励雷军99亿利润大降半年市值蒸发3000亿港元 泡椒回归36分威少三双雷霆惨遭逆转负步行者 如何养活饥饿的地球?技术、伦理缺一不可 还能不能吃药?大多数药物\"非活性成分\"或引起副作用 青岛海关查获2.8万张问题地图:错绘中印国界线 刘畊宏晒健身照老婆出镜魔鬼身材震惊众人! 苏杯国羽小组第一出线应无悬念李宗伟计划南宁复出 农大博士开发鸵鸟经济远销欧美日韩农户年均增收9万 故宫与华为合作:共同建设“5G智慧故宫” 日银决议如期维稳欧元、英镑、日元、澳纽最新分析 杨紫瘦身节目收官体验运动化妆等12种减肥方法 北京延庆取消5景区资质莲花山森林公园停止对外营业 给你打骚扰电话的可能不是人:AI电话营销一天一千通 网易考拉加拿大鹅鉴定结果出炉杭州滨江市监局:正品 英财政大臣建议调查谷歌Facebook垄断数字广告市… 驻埃塞俄比亚大使谈践约见埃塞航空首席执行官 一声叹息!最强175回顾绿军生涯若没走已夺冠 迪士尼收购福克斯交易完成员工陷入裁员恐慌 中国互金协会:不得开展高息现金贷等违规活动 外媒:法国机构将协助埃航分析失事客机黑匣子 中国人将比美国人更长寿 美国原油库存大降958万桶创2018年7月来最大降幅 市场怎么走,要看这一领先指标! 日高官在韩机场涉嫌醉酒打人大喊“我恨韩国人” Lyft称将努力降低保险成本并率先推出无人驾驶的士 贾跃亭继续卖楼续命:FF出售洛杉矶办公总部改为租用 彭昱畅在线送鼓励劝粉丝认真上课别学小蒙总 郭京飞回应“殴打明玉”:姚晨躺着,我打的只是空气 热点:解读跨国公司跨境资金集中运营新政 纽约凉了之后亚马逊另一第二总部也面临新资金投票 今天“地主”贾跃亭做了一个艰难的决定! 美国监管机构为应对英国硬脱欧风险推暂行最终规则 国君策略:短期交易集中风险释放行情上涨逻辑未改 瑞信下调腾讯音乐评级至中性周三股价大跌10.29% 葡联赛-蒋泽军中场策划绝平进球徐启功疑似点球未吹 餐饮业竞争加剧,国际餐饮巨头拿出“杀手锏” 作为消费者,这些坑一定有你没躲过的 美国跨境电商法律咨询五十问 否决脱欧协议又不同意无协议脱欧英国的选择不多了 正荣金融:联储局维持低息恒指应可稳守29000点水平 买表许你胜过春风十里送给爱人的最棒礼物 苹果供应商JDI正寻求中国投资以减轻财务负担 美又阻挠华为海底电缆项目专家:典型的做贼心虚 彭程订俩睡袋给男伴带温暖金杨:她是我的军师 央行:2018年移动支付业务量快速增长共处理605亿… 韩德君现身海南三亚的餐厅推测将无缘季后赛 贝佐斯婚外情最新进展:情妇哥哥收了20万美元爆料费 深圳伦敦有望在金融科技等六大领域展开合作 赵涛贾樟柯与李沧东等人聚会牛仔情侣外套很抢镜 李若彤亲自翻看网友评论提及“过儿”忍俊不禁 神吐槽:勇士队这真的不是在合力演杜兰特么? 金沙中国建议派末期息每股1元 “714高炮”曝光:多方摸排高息现金贷 韩国反垄断监管机构降低对高通处罚至2亿美元 以激进行动应对美国压力任正非对CNN披露原因 林肯下调全系车型售价,最高降2万元 谢楠细心指导儿子骑平衡车一身休闲装扮舒适矫健 全球250名科学家警告无线耳机致癌?事实是这样的 欧盟将召开新闻发布会:或宣布对谷歌AdSense罚款 蔡健雅晒与王源王景春合影男帅女靓画面很养眼 全国人大代表卢玉胜建议:加强政企协作打击网络刷单 德意志银行和德国商业银行正在进行合并谈判 龟梨和也被拍深夜约会对象是两名金发白人美女 又是3%!湖人再这样打下去,要笑疯了! 李小璐和贾乃亮分居?公司紧急否认,但这些细节让人细思极… 卡纳瓦罗遇“开门黑”中国男足0比1不敌泰国无缘中国… 关于3G退网,多的是你不知道的事儿 直击|红米卢伟冰怼荣耀旗舰:价格一半性能完全媲美 超半数球迷认为卡纳瓦罗已经尽力这结果早预料到 麦格理:耐世特目标价降至12.5元评级跑赢大市 这家外资零售商曾是\"高冷\"巨兽如今频繁\"被出售… 中国石油去年净利润525.91亿元同比增长130.7… 美拟向太平洋地区增兵数千:“动态部署”于伙伴国 越过短期危机,波音的长期前景是怎样的? 电子烟何去何从?产业链保持\"镇定\"但监管或在不远处 专访太舞滑雪小镇总裁:和新浪合作更具吸引力 信达生物:全年亏损近15亿产品上市后销售能力待考 每天喝飲料喝成一口爛牙牙醫建議一次喝完 2019中国房地产开发企业综合发展10强:恒大居榜首 跨境电商纠纷明显增多:网易考拉小红书等被法院点名 国有林区违建私人庄园“曹园”的背景有多深? 好未来法定代表人发生变更:罗戎退出樊保荣接任 “打假”变“假打” “职业打假”竟成产业链 羽生也太火了!世锦赛门票价格翻5倍训练票都卖钱 空置税要来了香港楼市已吓趴内地会跟进吗? 前央视主持人毕福剑近照曝光,身材发胖,像老了好几岁! 香港证监会出手“亮剑”4家国际巨头被罚8亿港元 川普总统的贸易战“成绩单”:哪些美国人在为其买单 砸手里了!曼联大水货表态不愿离队还想拿冠军 美国纽约市出动大批武装警察持枪守卫清真寺 萨里:不知道阿扎尔和皇马啥情况不想踢我不强求 为何说神州租车的确定性要归功于这几大“杠杆”? 庄神21+21八号秀27分杀死比赛活塞遭骑士爆冷 甜甜圈品牌美仕唐纳滋退出中国大陆费用上涨难维持 大和:吉利汽车目标价升至18.2元维持买入评级 龙湖集团:捐资1亿元人民币设立\"龙湖-故宫文化基金\… 骗取书画1200万元的副省长一审被判14年 加拿大经济全面崩盘加元兑人民币汇率将会跌至4.3 德国拟设立国有基金保护关键企业不被外资收购 对于中国崛起默克尔说了句公道话 大兴国际机场国际航线再添5条包括大兴至巴黎航线 陈立农李现双男主出演奇幻古装片《春江花月夜》 YG涉嫌海外转移资产首尔国税局对其展开调查 罗马有意皇马后场万金油连追几个赛季今夏最有戏 卡雙子星?經長:不是經濟部說了算 跨界加盟\"小李子\"将任私募股权公司Princev… 百度申请多项无人驾驶汽车相关专利 研究机构:德国经济增速今年可能会剧烈放缓 库里这地位没谁了!老板开飞机带他去这里庆生 沃尔沃汽车下调厂商建议零售价XC90最高降幅达6万 赛前训练日俄女单擦出火花扎吉托娃让日媒惊叹 全国雪橇冠军赛在俄罗斯举行范铎耀斩获男子冠军 郑俊英再被首尔地方警察厅传唤暂已回家 苹果与斯坦福心脏监测结果:为2000用户发送风险提醒 盐城化工厂爆炸:环境部工作组赶赴盐城指导应急工作 違法廣告醫材 理科太太、慧智基因各罰20萬元 分析师:流媒体视频服务有望每年为苹果创收100亿美元 重罚!丹麦羽毛球选手因赌球被禁赛18个月 桥水基金达利欧:多样化组合投资是最重要的事 BIGBANG某官号封面还是胜利专业人士曝年底回归 交银国际:吉利目标价上调35%至17.5元维持买入评… 英央行议息带来交易机会巧用外汇相关性分散风险 美瑞健康有意融资拓展大麻业务股份现挫逾一成 华宝股份24.6亿土豪分红背后:精心排练的圈钱新套路 曝PSA集团合并FCA的提议遭到拒绝 近观“部长通道”:有“民生温度”有“家国情怀” 【收藏帖】解读外资高效选股的独家秘笈 1挑4准绝杀!为了一个盖帽命都不要了? 杨紫晒梦幻清新写真自侃不自拍光影朦胧侧颜精致 甘肃:全省所有校园及周边200米范围内禁售辣条 台媒:新西兰枪击案凸显移民问题引发“白人焦虑” 神吐槽|哈登抱着豪斯大声喊:ThisismyHO… 陷资金困境FF再出售洛杉矶总部大楼 约老师21+17掘金6连胜紧追勇士有望创造队史 周黑鸭的燃眉之急:如何提升业绩打脸做空机构? 2019篮球世界杯抽签:美国E组上海战日本土耳其 曝皇马计划卖球员多赚1.5亿J罗等人进清洗名单 春秋航空一航班遇大风无法降落后返航乘客:像过山车 波音737Max防失速系统存缺陷美联邦航空局饱受质… 俄媒点赞中国果断停飞波音737MAX:生命比收入重要 Facebook游戏界面改版:新增游戏标签上架游戏A… 日本2月核心通胀率小幅下滑实现通胀目标任重道远 韩娱乐圈“性丑闻”再升级文在寅:赌上命运彻查 安徽亳州市委副书记陈军新添兼职:市委政法委书记 趣店的飞轮效应:26.8亿净利润从何而来? “大数据杀熟”愈演愈烈电商诚信修复成系统工程 一图流|退役后彻底放飞!邓肯的发型越来越朋克 蔺海波任兰州大学党委副书记此前在东北林大任职 省属国企高官忏悔录:没正确对待当官和发财的关系 这双“天眼”看得更清,测得更准 吃完800块豆干最好吃的原来是这5块 武磊终于输了!遭遇西甲生涯首场失利2胜4平1负 南投縣文化局推南投市文化尋寶地圖 融信中国:委任余丽娟为执行董事 网络直播屡屡闹出人命自律不足致直播业乱象迭生 野村:旭辉控股目标价升至6.15元给予买入评级 世界战机研发奇迹:歼轰-7研制费只相当于一架F-35 互金、共享出行成去年投诉“大户”2019年慎防新雷区 游泳名将猝死杜敬谦非首例7年前世界冠军也曾遭难 3000点之后怎么走?4位选基金“能手”来帮你 日本东证所拟要求主板企业维持至少250亿日元市值 中国太平:1-2月原保险保费收入升8.03%至508.…